Evaluation Of Online Cognitive Tracking To The Treatment Of Alzheimer's Patients Receiving Donepezil, Memantine, And Combination Therapy

Nilgün Çınar1, Meral Bozdemir2, Elif Bayındır3, Türker Sahiner4.

Neurology Dept., Memorial Hospitals, Istanbul, Turkey. (turker.sahiner@memorial.com.tr) (www.beynex.com)

Abstract:

Background: This study aimed to evaluate the effect of digital cognitive monitoring using the Beynex platform on cognitive performance and clinical outcomes in people living with Alzheimer’s condition who were receiving different pharmacological treatments.

Methods: A phase 4 single-blind clinical trial was conducted with 180 participants across three drug groups (Ebicomb, Donepezil, and Memantin). Participants were followed over three visits (baseline, mid-term, and 6-month). The Beynex group used the digital platform for continuous cognitive monitoring and feedback, while the control group received only standard pharmacological treatment. Cognitive and functional outcomes were assessed using the Montreal Cognitive Assessment (MoCA), Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-COG), Geriatric Depression Scale (GDS), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), and a clinical dementia rating measure. Mixed-design ANOVA analyses were performed with factors of Time, Drug, and Beynex use

Results: Significant interactions were found between Time and Beynex for both MoCA (p < .001) and ADAS-COG (p = .029), showing different cognitive trajectories between groups. Participants using Beynex demonstrated stable or improved cognitive scores (MoCA mean ↑ 16.9→17.5; ADAS-COG mean ↓ 15.6→14.2), whereas non-users declined over time. Beynex use was also associated with a lower mean dementia severity score (p = .010), indicating milder clinical progression. Functional ability and mood remained largely stable across groups. No drug-specific effects or interactions were observed.

Conclusion: Digital cognitive monitoring through Beynex was linked to better preservation of cognitive function and lower dementia severity, independent of medication type. These findings highlight the potential of combining pharmacological treatment with digital tools to support sustained cognitive health and person-centered care in Alzheimer’s